Gastroenterology
Volume 128, Issue 4 , Pages 870-881, April 2005

Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices

  • Rome Jutabha

      Affiliations

    • Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles Center for the Health Sciences, Los Angeles, California
  • ,
  • Dennis M. Jensen

      Affiliations

    • Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles Center for the Health Sciences, Los Angeles, California
    • Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California
    • Center for Ulcer Research and Education: Digestive Diseases Research Center, San Diego, California
    • Corresponding Author InformationAddress requests for reprints to: Dennis M. Jensen, MD, CURE/Digestive Disease Research Center, WLA VA Medical Center, Building 115, Room 318, 11301 Wilshire Boulevard, Los Angeles, California 90073-1003; fax: (310) 794-2908.
  • ,
  • Paul Martin

      Affiliations

    • Cedars Sinai Medical Center, San Diego, California
  • ,
  • Thomas Savides

      Affiliations

    • University of California, San Diego Medical Center, San Diego, California
  • ,
  • Steven-Huy Han

      Affiliations

    • Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles Center for the Health Sciences, Los Angeles, California
  • ,
  • Jeffrey Gornbein

      Affiliations

    • Department of Biomathematics, University of California, Los Angeles, California

Received 27 December 2003; accepted 7 January 2005.

Background & Aims: Standard care for prevention of first esophageal variceal hemorrhage is β-blockade, but this may be ineffective or unsafe. Our purpose was to compare endoscopic banding with propranolol for prevention of first variceal hemorrhage. Methods: In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by ≥25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months. The primary end point was treatment failure, defined as the development of endoscopically documented variceal hemorrhage or a severe medical complication requiring discontinuation of therapy. Direct costs were estimated from Medicare reimbursements and fixed or variable charges for services up to treatment failure. Results: Background variables of the treatment groups were similar. The trial was stopped early after an interim analysis showed that the failure rate of propranolol was significantly higher than that of banding (6/31 vs. 0/31; difference, 19.4%; P = .0098; 95% confidence interval for true difference, 6.4%–37.2%). Significantly more propranolol than banding patients had esophageal variceal hemorrhage (4/31 vs. 0/31; difference, 12.9%; P = .0443; 95% confidence interval for true difference, 0.8%–29%), and the cumulative mortality rate was significantly higher in the propranolol than in the banding group (4/31 vs. 0/31; difference, 12.9%; P = .0443; 95% confidence interval for true difference, 0.8%–29%). Direct costs of care were not significantly different. Conclusions: For patients with cirrhosis with high-risk esophageal varices and no history of variceal hemorrhage, propranolol-treated patients had significantly higher failure rates of failure, first esophageal varix hemorrhage, and cumulative mortality than banding patients. Direct costs of medical care were not significantly different.

Abbreviations used in this paper:  CI, confidence interval , GEJ, gastroesophageal junction , HVPG, hepatic venous pressure gradient , OLT, orthotopic liver transplantation , TIPS, transjugular intrahepatic portosystemic shunt , UGI, upper gastrointestinal tract

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The study and investigators were supported in part by the following grants: NIH Clinical Associate Physician Award (R.J.), American Society for Gastrointestinal Endoscopy Research Award (R.J.), NIH NIDDK IK24 DK 02650 Grant (D.M.J.), NIH NIDDK 41301 (CURE CORE grant), and NIH General Clinical Research Center—PHS Grant 5 MO1-RR008658-25.

PII: S0016-5085(05)00159-9

doi:10.1053/j.gastro.2005.01.047

Gastroenterology
Volume 128, Issue 4 , Pages 870-881, April 2005